PL2895484T3 - Inhibitory syntazy glukozyloceramidowej - Google Patents
Inhibitory syntazy glukozyloceramidowejInfo
- Publication number
- PL2895484T3 PL2895484T3 PL13765893.6T PL13765893T PL2895484T3 PL 2895484 T3 PL2895484 T3 PL 2895484T3 PL 13765893 T PL13765893 T PL 13765893T PL 2895484 T3 PL2895484 T3 PL 2895484T3
- Authority
- PL
- Poland
- Prior art keywords
- synthase inhibitors
- glucosylceramide synthase
- glucosylceramide
- inhibitors
- synthase
- Prior art date
Links
- 239000003892 ceramide glucosyltransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699714P | 2012-09-11 | 2012-09-11 | |
| PCT/US2013/058896 WO2014043068A1 (en) | 2012-09-11 | 2013-09-10 | Glucosylceramide synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2895484T3 true PL2895484T3 (pl) | 2022-10-03 |
Family
ID=49226563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13765893.6T PL2895484T3 (pl) | 2012-09-11 | 2013-09-10 | Inhibitory syntazy glukozyloceramidowej |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US20150210681A1 (pl) |
| EP (2) | EP2895484B1 (pl) |
| JP (1) | JP6430943B2 (pl) |
| KR (1) | KR102216532B1 (pl) |
| CN (3) | CN108864076B (pl) |
| AR (1) | AR092522A1 (pl) |
| AU (1) | AU2013315715A1 (pl) |
| BR (1) | BR112015005227A2 (pl) |
| CA (1) | CA2884144C (pl) |
| CL (1) | CL2015000529A1 (pl) |
| CR (1) | CR20150150A (pl) |
| DK (1) | DK2895484T3 (pl) |
| DO (1) | DOP2015000039A (pl) |
| EA (2) | EA202091568A1 (pl) |
| ES (1) | ES2911685T3 (pl) |
| GT (1) | GT201500051A (pl) |
| HR (1) | HRP20220310T1 (pl) |
| HU (1) | HUE058085T2 (pl) |
| IL (1) | IL237355B (pl) |
| JO (1) | JOP20130273B1 (pl) |
| LT (1) | LT2895484T (pl) |
| MA (1) | MA37975B2 (pl) |
| MX (2) | MX387333B (pl) |
| MY (1) | MY186824A (pl) |
| NZ (1) | NZ706296A (pl) |
| PE (1) | PE20150734A1 (pl) |
| PH (1) | PH12015500431B1 (pl) |
| PL (1) | PL2895484T3 (pl) |
| PT (1) | PT2895484T (pl) |
| RS (1) | RS63130B1 (pl) |
| SG (2) | SG10201701966RA (pl) |
| SI (1) | SI2895484T1 (pl) |
| TN (1) | TN2015000091A1 (pl) |
| TW (1) | TWI627171B (pl) |
| UA (1) | UA118747C2 (pl) |
| UY (1) | UY35024A (pl) |
| WO (1) | WO2014043068A1 (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| KR20150130386A (ko) | 2013-03-15 | 2015-11-23 | 젠자임 코포레이션 | 글루코실세라마이드 신타아제 저해제의 제조 방법 |
| CN117679415A (zh) * | 2013-12-11 | 2024-03-12 | 建新公司 | 葡糖神经酰胺合酶抑制剂 |
| FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
| AU2015301278A1 (en) * | 2014-08-04 | 2017-02-09 | Genzyme Corporation | Biomarkers of polycystic kidney disease and uses thereof |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| WO2016141458A1 (en) | 2015-03-12 | 2016-09-15 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| MX2018006250A (es) * | 2015-11-18 | 2018-09-05 | Genzyme Corp | Biomarcador de enfermedad poliquistica renal y usos del mismo. |
| EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| HUE057838T2 (hu) | 2016-06-07 | 2022-06-28 | Jacobio Pharmaceuticals Co Ltd | SHP2 inhibitorokként hasznos új heterociklusos származékok |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| TWI664175B (zh) | 2017-03-23 | 2019-07-01 | 大陸商北京加科思新藥研發有限公司 | 用於作為shp2抑制劑之新穎雜環衍生物 |
| CN109111447A (zh) | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途 |
| EP3728265A1 (en) | 2017-12-21 | 2020-10-28 | BIAL - BioTech Investments, Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
| EP3774732A4 (en) * | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN109709202A (zh) * | 2018-12-29 | 2019-05-03 | 辉源生物科技（上海）有限公司 | 一种半乳糖神经酰胺转移酶抑制剂药物的快速筛选方法 |
| PL3920912T3 (pl) * | 2019-02-04 | 2025-11-12 | Genzyme Corporation | Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs) |
| CN114269331A (zh) * | 2019-03-28 | 2022-04-01 | 埃萨制药股份有限公司 | 雄激素受体调节剂和用作蛋白水解靶向嵌合体配体的方法 |
| US12109179B2 (en) | 2019-03-28 | 2024-10-08 | Essa Pharma Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| US11459336B2 (en) | 2019-06-14 | 2022-10-04 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| PH12021552839A1 (en) | 2019-06-14 | 2022-10-03 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| US11618750B2 (en) | 2019-06-14 | 2023-04-04 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators |
| CN113993583A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途 |
| AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
| BR112021024117A2 (pt) | 2019-06-14 | 2022-03-22 | Janssen Pharmaceutica Nv | Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| WO2021020362A1 (ja) | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | 複素環化合物 |
| US20220274982A1 (en) | 2019-07-29 | 2022-09-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR102483492B1 (ko) * | 2019-09-02 | 2023-01-02 | 한양대학교 에리카산학협력단 | 2,5-이치환된 피리미딘 유도체 및 이를 포함하는 약학적 조성물 |
| US20230002379A1 (en) | 2019-11-15 | 2023-01-05 | Yuhan Corporation | Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
| JP7636409B2 (ja) * | 2019-11-15 | 2025-02-26 | ユーハン・コーポレイション | １，２，３，４－テトラヒドロナフタレン基を有する新規な誘導体またはその薬学的に許容可能な塩及びこれらを含む医薬組成物 |
| CN115427038A (zh) * | 2020-02-03 | 2022-12-02 | 建新公司 | 治疗与溶酶体贮积病相关的神经系统症状的方法 |
| US20210323931A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
| AU2021311131A1 (en) | 2020-07-24 | 2023-03-23 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
| CA3216293A1 (en) * | 2021-05-11 | 2022-11-17 | Dong-Hoon Kim | Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the sam |
| US20250026762A1 (en) * | 2021-11-30 | 2025-01-23 | Merck Sharp & Dohme Llc | Fused pyrazole urea analogs as glucosylceramide synthase inhibitors |
| EP4490148A2 (en) * | 2022-03-11 | 2025-01-15 | Merck Sharp & Dohme LLC | Non-aromatic cyclic-pyrimidine analogs as glucosylceramide synthase inhibitors |
| US20250171467A1 (en) * | 2022-03-14 | 2025-05-29 | Merck Sharp & Dohme Llc | Fused pyrazole amide analogs as glucosylceramide synthase inhibitors |
| IL321165A (en) | 2022-12-01 | 2025-07-01 | Genzyme Corp | Vanglustat in combination with a strong or moderate CYP3A4 inhibitor |
| KR20250117295A (ko) * | 2024-01-26 | 2025-08-04 | 주식회사유한양행 | 고셔병의 예방 또는 치료용 약제학적 조성물 |
| WO2025221055A1 (ko) * | 2024-04-18 | 2025-10-23 | 에스케이바이오팜 주식회사 | 유레아 화합물 및 이의 용도 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB725228A (en) | 1952-06-19 | 1955-03-02 | Roche Products Ltd | Substituted carbamic acid esters and process for the manufacture thereof |
| BE640616A (pl) | 1962-12-19 | |||
| NL130759C (pl) | 1965-10-07 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4593034A (en) * | 1984-04-06 | 1986-06-03 | A. H. Robins Company, Inc. | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides |
| IE63474B1 (en) | 1987-12-24 | 1995-04-19 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| ATE85217T1 (de) * | 1988-08-04 | 1993-02-15 | Synthelabo | Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.>oct-3-yl)benzamide und thiobenzamide. |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| IT1228293B (it) | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
| DK443489D0 (da) | 1989-09-08 | 1989-09-08 | Ferrosan As | Substituerede urinstofforbindelser, deres fremstilling og anvendelse |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| GB9106571D0 (en) | 1991-03-27 | 1991-05-15 | Erba Carlo Spa | Derivatives of substituted imidazol-2-one and process for their preparation |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| KR970701174A (ko) * | 1994-02-10 | 1997-03-17 | 오노다 마사요시 | 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same) |
| US5468875A (en) * | 1994-12-22 | 1995-11-21 | American Home Products Corporation | 1-azabicycloheptane derivatives |
| JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
| WO1997017348A1 (en) | 1995-11-08 | 1997-05-15 | American Home Products Corporation | 1-azabicycloheptane derivatives and their pharmaceutical use |
| SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| WO1998004517A1 (en) | 1996-07-29 | 1998-02-05 | Pharmacia & Upjohn Ab | Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation |
| EP2147681A1 (en) | 1997-10-29 | 2010-01-27 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
| WO2000026186A1 (en) * | 1998-11-02 | 2000-05-11 | Welfide Corporation | Pyrrolidine compounds and medicinal utilization thereof |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
| SK12712002A3 (sk) | 2000-02-07 | 2003-02-04 | Abbott Gmbh & Co. Kg | Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| US6916828B2 (en) | 2000-06-27 | 2005-07-12 | Laboratorios S.A.L.V.A.T., S.A. | Carbamates derivatived from arylakylamines |
| US6492386B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| AU2002228015B2 (en) | 2000-12-22 | 2007-08-23 | Almirall, S.A. | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| EP1231212B1 (en) | 2001-02-06 | 2006-12-20 | Pfizer Products Inc. | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders |
| JP2003267977A (ja) | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
| DE10211415A1 (de) * | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| CA2492404C (en) | 2002-07-17 | 2012-02-07 | Oxford Glycosciences (Uk) Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
| JPWO2004011430A1 (ja) | 2002-07-25 | 2005-11-24 | アステラス製薬株式会社 | ナトリウムチャネル阻害剤 |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| CN102657651A (zh) | 2002-12-06 | 2012-09-12 | 范因斯坦医学研究院 | 用α 7受体结合胆碱能激动剂抑制炎症 |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| TW200529860A (en) | 2003-12-22 | 2005-09-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| JP2007186422A (ja) | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
| AU2005258274A1 (en) | 2004-06-23 | 2006-01-05 | The Feinstein For Medical Research | Method of treating ileus by pharmacological activation of cholinergic receptors |
| US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| US20090131470A1 (en) * | 2005-06-11 | 2009-05-21 | Vernalis R & D Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| AU2006295397A1 (en) * | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| SG131819A1 (en) | 2005-11-07 | 2007-05-28 | Chikka Pte Ltd | Buddy-based cross-carrier messaging system |
| BRPI0707245A2 (pt) * | 2006-01-23 | 2011-04-26 | Crystalgenomics Inc | derivados de imidazopiridina que inibem a atividade de proteìna quinase, método para a preparação destes e composição farmacêutica contendo os mesmos |
| EP1984370A4 (en) | 2006-01-23 | 2010-03-31 | Crystalgenomics Inc | PROTEIN KINASE ACTIVITY INHIBITING IMIDAZOPYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF |
| US20090318491A1 (en) | 2006-01-27 | 2009-12-24 | Yale Univeristy | Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders |
| US7840109B2 (en) | 2006-08-14 | 2010-11-23 | Adc Telecommunications, Inc. | Factory spliced cable assembly |
| CN101605784B (zh) * | 2007-02-09 | 2013-04-10 | 安斯泰来制药株式会社 | 氮杂桥环化合物 |
| JP2010523578A (ja) | 2007-03-30 | 2010-07-15 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いるファブリー病の治療方法 |
| EP2546232A1 (en) * | 2007-06-20 | 2013-01-16 | Merck Sharp & Dohme Corp. | Diphenyl Substituted Alkanes |
| GB2466912B (en) | 2007-11-29 | 2012-01-04 | Hospital For Sick Children | Compositions and methods for treating lysosomal disorders |
| JP2011529500A (ja) | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
| EP2154136A1 (en) * | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| JP5731479B2 (ja) | 2009-04-21 | 2015-06-10 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｈｓｐ９０阻害剤としてのレゾルシノール誘導体 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| US20120157464A1 (en) | 2009-07-23 | 2012-06-21 | Novartis Ag | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia |
| PL2470199T3 (pl) | 2009-08-28 | 2019-11-29 | Icahn School Med Mount Sinai | Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy |
| US20110183938A1 (en) | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
| RU2643807C1 (ru) | 2010-11-12 | 2018-02-06 | Сионоги Энд Ко., Лтд. | Кристаллы производных 6,7-ненасыщенного-7-карбамоилморфинана и способ их получения |
| UA118248C2 (uk) | 2011-03-18 | 2018-12-26 | Джензім Корпорейшн | Інгібітори глюкозилцерамідсинтази |
| EP2723734A1 (en) | 2011-06-22 | 2014-04-30 | Isochem | Process for the preparation of solifenacin and salts thereof |
| WO2012177997A1 (en) | 2011-06-22 | 2012-12-27 | The General Hospital Corporation | Treatment of proteinopathies |
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| AU2013316779A1 (en) | 2012-09-11 | 2015-04-02 | Hospira Australia Pty Ltd. | Daptomycin formulations and uses thereof |
| JO3713B1 (ar) | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| KR20150130386A (ko) | 2013-03-15 | 2015-11-23 | 젠자임 코포레이션 | 글루코실세라마이드 신타아제 저해제의 제조 방법 |
| CN117679415A (zh) | 2013-12-11 | 2024-03-12 | 建新公司 | 葡糖神经酰胺合酶抑制剂 |
| TW201642855A (zh) | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| PL3920912T3 (pl) | 2019-02-04 | 2025-11-12 | Genzyme Corporation | Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs) |
| SG11202107844UA (en) | 2019-02-04 | 2021-08-30 | Genzyme Corp | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
| CN115427038A (zh) | 2020-02-03 | 2022-12-02 | 建新公司 | 治疗与溶酶体贮积病相关的神经系统症状的方法 |
-
2013
- 2013-09-09 JO JOP/2013/0273A patent/JOP20130273B1/ar active
- 2013-09-09 MA MA37975A patent/MA37975B2/fr unknown
- 2013-09-10 WO PCT/US2013/058896 patent/WO2014043068A1/en not_active Ceased
- 2013-09-10 PL PL13765893.6T patent/PL2895484T3/pl unknown
- 2013-09-10 PT PT137658936T patent/PT2895484T/pt unknown
- 2013-09-10 BR BR112015005227A patent/BR112015005227A2/pt not_active Application Discontinuation
- 2013-09-10 HU HUE13765893A patent/HUE058085T2/hu unknown
- 2013-09-10 US US14/427,275 patent/US20150210681A1/en not_active Abandoned
- 2013-09-10 ES ES13765893T patent/ES2911685T3/es active Active
- 2013-09-10 EA EA202091568A patent/EA202091568A1/ru unknown
- 2013-09-10 MX MX2020002867A patent/MX387333B/es unknown
- 2013-09-10 CN CN201810581322.8A patent/CN108864076B/zh active Active
- 2013-09-10 MX MX2015003043A patent/MX377735B/es active IP Right Grant
- 2013-09-10 JP JP2015531307A patent/JP6430943B2/ja active Active
- 2013-09-10 EP EP13765893.6A patent/EP2895484B1/en active Active
- 2013-09-10 SG SG10201701966RA patent/SG10201701966RA/en unknown
- 2013-09-10 CN CN201380058586.0A patent/CN105073745B/zh active Active
- 2013-09-10 CN CN202210106457.5A patent/CN114533729A/zh active Pending
- 2013-09-10 EA EA201590554A patent/EA038536B1/ru not_active IP Right Cessation
- 2013-09-10 AU AU2013315715A patent/AU2013315715A1/en not_active Abandoned
- 2013-09-10 LT LTEPPCT/US2013/058896T patent/LT2895484T/lt unknown
- 2013-09-10 CA CA2884144A patent/CA2884144C/en active Active
- 2013-09-10 PE PE2015000308A patent/PE20150734A1/es unknown
- 2013-09-10 SI SI201331971T patent/SI2895484T1/sl unknown
- 2013-09-10 KR KR1020157009037A patent/KR102216532B1/ko active Active
- 2013-09-10 DK DK13765893.6T patent/DK2895484T3/da active
- 2013-09-10 MY MYPI2015000454A patent/MY186824A/en unknown
- 2013-09-10 HR HRP20220310TT patent/HRP20220310T1/hr unknown
- 2013-09-10 EP EP22154095.8A patent/EP4098654A1/en active Pending
- 2013-09-10 SG SG11201501538VA patent/SG11201501538VA/en unknown
- 2013-09-10 RS RS20220379A patent/RS63130B1/sr unknown
- 2013-09-10 NZ NZ706296A patent/NZ706296A/en unknown
- 2013-09-11 AR ARP130103240A patent/AR092522A1/es unknown
- 2013-09-11 UY UY0001035024A patent/UY35024A/es unknown
- 2013-09-11 TW TW102132762A patent/TWI627171B/zh active
- 2013-10-09 UA UAA201503339A patent/UA118747C2/uk unknown
-
2015
- 2015-02-22 IL IL237355A patent/IL237355B/en active IP Right Grant
- 2015-02-25 DO DO2015000039A patent/DOP2015000039A/es unknown
- 2015-02-27 PH PH12015500431A patent/PH12015500431B1/en unknown
- 2015-03-02 GT GT201500051A patent/GT201500051A/es unknown
- 2015-03-04 CL CL2015000529A patent/CL2015000529A1/es unknown
- 2015-03-10 TN TNP2015000091A patent/TN2015000091A1/fr unknown
- 2015-03-19 CR CR20150150A patent/CR20150150A/es unknown
-
2017
- 2017-04-18 US US15/490,385 patent/US11008316B2/en active Active
-
2021
- 2021-04-14 US US17/230,385 patent/US12060349B2/en active Active
-
2024
- 2024-07-19 US US18/777,773 patent/US20250026749A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237355B (en) | Glucosylceramide synthase inhibitors | |
| ZA201307016B (en) | Glucosylceramide synthase inhibitors | |
| ZA201407554B (en) | Dna-pk inhibitors | |
| HUE048834T2 (hu) | Kináz inhibitorok | |
| IL232958A (en) | Kinase inhibitors | |
| IL229028A0 (en) | Kinase inhibitors | |
| IL245737B (en) | Glucosylceramide synthase inhibitors | |
| IL232959A (en) | Kinase inhibitors | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| AU2019222801A1 (en) | Glucosylceramide synthase inhibitors | |
| AU2018200675A1 (en) | Glucosylceramide synthase inhibitors | |
| SG10201602022UA (en) | Glucosylceramide synthase inhibitors |